Key Takeaway
Choosing a GLP-1 medication can feel overwhelming. There are multiple options on the market, each with different dosing schedules, efficacy profiles, side effects, and costs.
Choosing a GLP-1 medication can feel overwhelming. There are multiple options on the market, each with different dosing schedules, efficacy profiles, side effects, and costs. A clear GLP-1 medication comparison chart helps you see the differences side by side so you can have a more informed conversation with your provider.
Key Takeaways: - GLP-1 Medications: The Full Lineup - Multi-Agonist Medications: The Next Generation - Side-by-Side: Efficacy, Side Effects, and Dosing - Cost and Access: What You Need to Know - Learn how to choose the right glp-1 medication
This guide breaks down every major GLP-1 and multi-agonist medication currently available. We cover how well each one works, what side effects to expect, how often you take it, and what it costs. If you are just starting your research or narrowing down your options, this comparison will give you the facts you need.
GLP-1 Medications: The Full Lineup
The GLP-1 receptor agonist class includes several medications. Each one mimics the natural GLP-1 hormone your gut produces after eating. They all reduce appetite and help control blood sugar. But they differ in important ways.
Semaglutide is one of the most widely studied GLP-1 medications. Clinical trials (STEP program) showed average weight loss of approximately 14.9% of body weight over 68 weeks at the 2.4 mg dose. It is taken as a once-weekly injection. Semaglutide is also available in oral form, though the injectable version has shown stronger weight loss results. FormBlends offers prescribed by licensed providers and prepared by US-based 503A pharmacies.
Liraglutide was one of the first GLP-1 medications approved for weight management. It requires daily injections. Clinical trials showed average weight loss of about 8% of body weight. It remains an option for people who prefer to start with a lower-potency medication or who have specific medical reasons to choose it.
Dulaglutide is primarily prescribed for type 2 diabetes management. It is a once-weekly injection. Weight loss results are moderate) typically 3-5% of body weight. It is less commonly used for weight management as a primary goal.
Exenatide comes in both twice-daily and once-weekly formulations. It was one of the earliest GLP-1 medications. Weight loss tends to be modest. It is more commonly used for blood sugar management than weight loss.
Lixisenatide is a once-daily injection used mainly for type 2 diabetes. Weight loss effects are minimal compared to newer options.
Free Download: GLP-1 Medication Comparison One-Pager Every GLP-1 medication compared in one printable chart (efficacy, dosing, side effects, and cost at a glance. Get yours free) we'll email it to you instantly. [Download Now]
"The conversation about obesity needs to shift from willpower to biology. These medications work because obesity is a neuroendocrine disease, not a character flaw.", Dr. Fatima Cody Stanford, MD, MPH, Massachusetts General Hospital
Multi-Agonist Medications: The Next Generation
Beyond single-target GLP-1 drugs, newer medications target multiple hormone receptors at once. This approach may produce significantly greater weight loss.
Tirzepatide targets both GLP-1 and GIP receptors. In the SURMOUNT-1 (Jastreboff et al., NEJM, 2022) trial, the highest dose (15 mg weekly) produced average weight loss of 22.5% of body weight over 72 weeks. That makes it the most effective injectable weight loss medication with published phase 3 data. You can learn more about in our detailed breakdown.
Survodutide is a dual GLP-1/glucagon agonist currently in late-stage trials. Phase 2 data showed weight loss of up to 18.7% of body weight. It takes a different approach than tirzepatide by targeting glucagon instead of GIP alongside GLP-1.
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 2 trial results showed average weight loss of up to 24.2% of body weight at the highest dose over 48 weeks. It is still in clinical development.
Orforglipron is an oral GLP-1 medication in development. Early data suggests weight loss of approximately 14.7% over 36 weeks. If approved, it would offer a pill-based alternative to weekly injections.
The trend is clear: each new generation of medications targets more pathways and produces greater average weight loss. But even current options like compounded semaglutide and tirzepatide deliver clinically meaningful results for many people.
Wondering which medication fits your goals? to see your options.
Side-by-Side: Efficacy, Side Effects, and Dosing
Here is a simplified comparison of the most commonly prescribed options:
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.
Try the BMI Calculator →Semaglutide (injectable) - Average weight loss: ~15% of body weight - Dosing: Once weekly injection - Common side effects: Nausea, vomiting, diarrhea, constipation - Titration period: 16-20 weeks to reach maintenance dose
Tirzepatide - Average weight loss: ~20-22% of body weight - Dosing: Once weekly injection - Common side effects: Nausea, diarrhea, decreased appetite, vomiting - Titration period: 20 weeks to reach maintenance dose
Liraglutide - Average weight loss: ~8% of body weight - Dosing: Daily injection - Common side effects: Nausea, diarrhea, constipation, headache - Titration period: 4-5 weeks to reach maintenance dose
All GLP-1 medications share similar gastrointestinal side effects. These tend to be worst during the titration phase when your dose is increasing. Most people find that side effects improve over time. Slow, gradual dose increases (which your provider will manage) help minimize discomfort.
If you experience side effects, tracking them can help your provider adjust your plan. The lets you log side effects, doses, and progress in one place. Having that data ready makes your provider visits more productive.
Cost and Access: What You Need to Know
Cost is often the deciding factor in choosing a GLP-1 medication. Brand-name medications can cost over $1,000 per month without insurance. Many insurance plans do not cover weight loss medications, or they require extensive prior authorization.
Compounded medications offer a more accessible option. FormBlends provides personalized compounded medications prepared by licensed US-based 503A pharmacies. These medications contain the same active ingredients prescribed by your provider, at a fraction of the brand-name cost. Check our to see current rates.
Here are some cost considerations:
- Brand-name semaglutide for weight management may cost $1,000-$1,400/month without insurance
- Brand-name tirzepatide for weight management may cost $1,000-$1,100/month without insurance
- Compounded semaglutide through FormBlends is significantly more affordable (see for current rates
- Liraglutide may cost $1,200-$1,500/month without insurance
Insurance coverage varies widely. Some plans cover GLP-1 medications for diabetes but not for weight management. Others require you to have a BMI above 30 (or above 27 with a weight-related health condition) and documented failure of other weight loss methods.
If cost is a barrier, compounded medications through a telehealth platform like FormBlends can make treatment accessible. Your provider can help you choose the most effective option within your budget.
How to Choose the Right GLP-1 Medication
With so many options, how do you decide? Here are the key factors your provider will consider:
Your weight loss goals. If you need to lose a significant amount of weight, a more potent option like compounded semaglutide or tirzepatide may be appropriate. For more modest goals, other options could work.
Your medical history. Certain conditions) like a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (are contraindications for GLP-1 medications. Your provider will review your full history.
Your tolerance for injections. Most GLP-1 medications are injectable. If needles are a concern, oral options exist, though they may have different efficacy profiles. Your provider can walk you through what to expect.
Your budget. cost varies significantly. Compounded options through FormBlends offer clinical-grade medications at more accessible price points.
Your lifestyle. Once-weekly injections fit most lifestyles better than daily dosing. Consider what schedule you can stick with consistently.
The best medication is the one you can take consistently and that your provider recommends based on your health profile. You can read more about or jump straight to a provider consultation.
Frequently Asked Questions
Which GLP-1 medication produces the most weight loss?
Based on published clinical trial data, tirzepatide has shown the highest average weight loss at approximately 22.5% of body weight at the highest dose. Semaglutide follows at approximately 15%. However, individual results vary, and the best medication for you depends on your complete health profile.
Are all GLP-1 medications the same?
No. While they all target the GLP-1 receptor, they differ in potency, dosing frequency, side effect profiles, and cost. Some newer medications also target additional receptors like GIP or glucagon. Your provider can explain which differences matter most for your situation.
Can I switch between GLP-1 medications?
Yes, switching is common. People may switch due to side effects, cost, availability, or because they want to try a more effective option. Your provider will manage the transition, including any dose adjustments needed. There is typically no washout period required.
How long do I need to take a GLP-1 medication?
GLP-1 medications work as long as you take them. Clinical trials have shown that most people regain weight after stopping. Many providers recommend long-term use combined with lifestyle changes. Your provider will help you develop a sustainable plan.
Does FormBlends offer compounded tirzepatide?
FormBlends connects you with licensed providers who can prescribe compounded GLP-1 medications, including both semaglutide and tirzepatide, based on your individual needs and eligibility. to learn what is available for you.
Let's Make This Happen
The research is clear. The options are available. The only question is whether it's right for you. A FormBlends provider can help you decide) no pressure, no commitment.
Sources & References
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. Doi:10.1056/NEJMoa1411892
- Marso SP, Daniels GH, Tanaka K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. Doi:10.1056/NEJMoa1603827
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Doi:10.1056/NEJMoa2032183
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 (Davies et al., Lancet, 2021)). Lancet. 2021;397(10278):971-984. Doi:10.1016/S0140-6736(21)00213-0
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3 (Wadden et al., JAMA, 2021)). JAMA. 2021;325(14):1403-1413. Doi:10.1001/jama.2021.1831
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5 (Garvey et al., Nat Med, 2022)). Nat Med. 2022;28:2083-2091. Doi:10.1038/s41591-022-02026-4
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. Doi:10.1056/NEJMoa2307563
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. Doi:10.1056/NEJMoa2206038
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2 (Garvey et al., Lancet, 2023)). Lancet. 2023;402(10402):613-626. Doi:10.1016/S0140-6736(23)01200-X
- Wadden TA, Chao AM, Engel S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3 (Wadden et al., Nat Med, 2023)). Nat Med. 2023. Doi:10.1038/s41591-023-02597-w
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4 (Aronne et al., JAMA, 2024)). JAMA. 2024;331(1):38-48. Doi:10.1001/jama.2023.24945
- Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391:1193-1205. Doi:10.1056/NEJMoa2404881
This article is for educational purposes only and does not constitute medical advice. Always consult with a licensed healthcare provider before starting, changing, or stopping any medication or supplement. FormBlends connects you with licensed providers who can evaluate your individual health needs.
Last updated: 2026-03-24